Q3 Trade Pfizer
Q3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab
Comentarios
28.8 needs some type of confirmation, whether it's a retest or very strong orders. This level is crucial for assessing the market's next moveComentarios
Small entry now 28.250Comentarios
locked in 50% with a 1.3% gain x40 levrage. Holding rest BOS
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.